Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000341632

Medchemexpress LLC Gsk3368715 dihydrochloride | 1628925-77-8 | 100.0% | 25 MG
SDP

Catalog No. 5000341632
Encompass_Preferred

GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor. It produces a shift in arginine methylation states, alters exon usage, and exhibits strong anti-cancer activity. This compound shows 50% or more growth inhibition relative to DMSO-treated cells in the majority of 249 cancer cell lines, representing 12 tumor types. In vivo, it significantly affects the growth of BxPC3 xenografts, reducing tumor growth by 78% and 97% in the 150- and 300-mg/kg dose groups, respectively.

  • Orally active
  • Reversible inhibitor
  • SAM uncompetitive type I PRMTs inhibitor
  • Shifts arginine methylation states
  • Alters exon usage
  • Exhibits strong anti-cancer activity
  • Inhibits growth in various cancer cell lines
  • Reduces tumor growth in BxPC3 xenografts

Catalog No. 50-003-41632 Supplier Medchemexpress LLC Supplier No. 25MGHY128717A
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor. It produces a shift in arginine methylation states, alters exon usage, and exhibits strong anti-cancer activity. This compound shows 50% or more growth inhibition relative to DMSO-treated cells in the majority of 249 cancer cell lines, representing 12 tumor types. In vivo, it significantly affects the growth of BxPC3 xenografts, reducing tumor growth by 78% and 97% in the 150- and 300-mg/kg dose groups, respectively.

  • Orally active
  • Reversible inhibitor
  • SAM uncompetitive type I PRMTs inhibitor
  • Shifts arginine methylation states
  • Alters exon usage
  • Exhibits strong anti-cancer activity
  • Inhibits growth in various cancer cell lines
  • Reduces tumor growth in BxPC3 xenografts

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.